Advanced search
1 file | 4.82 MB Add to list

Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity : results from two phase 3 prospective open-label studies

(2020) JOURNAL OF PEDIATRIC UROLOGY. 16(2). p.180.e1-180.e8
Author
Organization
Project
Keywords
Pediatrics, Perinatology, and Child Health, Urology

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 4.82 MB

Citation

Please use this url to cite or link to this publication:

MLA
Franco, Israel, et al. “Long-Term Efficacy and Safety of Solifenacin in Pediatric Patients Aged 6 Months to 18 Years with Neurogenic Detrusor Overactivity : Results from Two Phase 3 Prospective Open-Label Studies.” JOURNAL OF PEDIATRIC UROLOGY, vol. 16, no. 2, 2020, pp. 180.e1-180.e8.
APA
Franco, I., Hoebeke, P., Baka-Ostrowska, M., Bolong, D., Davies, L. N., Dahler, E., … Vande Walle, J. (2020). Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity : results from two phase 3 prospective open-label studies. JOURNAL OF PEDIATRIC UROLOGY, 16(2), 180.e1-180.e8.
Chicago author-date
Franco, Israel, Piet Hoebeke, Małgorzata Baka-Ostrowska, David Bolong, Leon N. Davies, Ellen Dahler, Robert Snijder, et al. 2020. “Long-Term Efficacy and Safety of Solifenacin in Pediatric Patients Aged 6 Months to 18 Years with Neurogenic Detrusor Overactivity : Results from Two Phase 3 Prospective Open-Label Studies.” JOURNAL OF PEDIATRIC UROLOGY 16 (2): 180.e1-180.e8.
Chicago author-date (all authors)
Franco, Israel, Piet Hoebeke, Małgorzata Baka-Ostrowska, David Bolong, Leon N. Davies, Ellen Dahler, Robert Snijder, Otto Stroosma, Frank Verheggen, Donald Newgreen, Brigitte Bosman, and Johan Vande Walle. 2020. “Long-Term Efficacy and Safety of Solifenacin in Pediatric Patients Aged 6 Months to 18 Years with Neurogenic Detrusor Overactivity : Results from Two Phase 3 Prospective Open-Label Studies.” JOURNAL OF PEDIATRIC UROLOGY 16 (2): 180.e1-180.e8.
Vancouver
1.
Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, et al. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity : results from two phase 3 prospective open-label studies. JOURNAL OF PEDIATRIC UROLOGY. 2020;16(2):180.e1-180.e8.
IEEE
[1]
I. Franco et al., “Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity : results from two phase 3 prospective open-label studies,” JOURNAL OF PEDIATRIC UROLOGY, vol. 16, no. 2, pp. 180.e1-180.e8, 2020.
@article{8658295,
  author       = {Franco, Israel and Hoebeke, Piet and Baka-Ostrowska, Małgorzata and Bolong, David and Davies, Leon N. and Dahler, Ellen and Snijder, Robert and Stroosma, Otto and Verheggen, Frank and Newgreen, Donald and Bosman, Brigitte and Vande Walle, Johan},
  issn         = {1477-5131},
  journal      = {JOURNAL OF PEDIATRIC UROLOGY},
  keywords     = {Pediatrics,Perinatology,and Child Health,Urology},
  language     = {eng},
  number       = {2},
  pages        = {180.e1--180.e8},
  title        = {Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity : results from two phase 3 prospective open-label studies},
  url          = {http://dx.doi.org/10.1016/j.jpurol.2019.12.012},
  volume       = {16},
  year         = {2020},
}

Altmetric
View in Altmetric